Y-mabs partner seeks launch of cancer drug in Brazil
Pharmaceutical company Adium Pharma has submitted drug Danyelza, developed by Y-Mabs, for Brazilian market authorization.
by ulrich quistgaard, translated by daniel pedersen
Y-mabs is hoping to soon see its cancer drug, Danyelza, on the market in Brazil, announcing in a press release that the company’s partner, Adium Pharma, has submitted a regulatory filing in the country.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.